Abstract
The global environment in which pharmaceutical and other medical companies operate is affected by the matter of EU enlargement both directly and indirectly. Key considerations arising are the Bolar Exemption and parallel importing. This paper looks at the current state of play regarding the 13 nations in line to join the EU, provides an overview of the Bolar Exemption and its implications for the medical industry and considers the effect that EU enlargement will have on parallel importing.
Get full access to this article
View all access options for this article.